Human medicines European public assessment report (EPAR): Eylea, aflibercept, Wet Macular Degeneration,Macular Edema,Diabetes Complications, Date of authorisation: 21/11/2012, Revision: 17, Status: Authorised

Case Medical Research ◽

10.31525/cmr-98d35a ◽

2019 ◽

Author(s):

Keyword(s):

Macular Degeneration ◽

Macular Edema ◽

Diabetes Complications ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 21/01/2007, Revision: 30, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996df ◽

2018 ◽

Author(s):

Keyword(s):

Macular Degeneration ◽

Macular Edema ◽

Diabetes Complications ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Wet Macular Degeneration,Macular Edema,Diabetes Complications, Date of authorisation: 21/11/2012, Revision: 17, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996e4 ◽

2019 ◽

Author(s):

Keyword(s):

Macular Degeneration ◽

Macular Edema ◽

Diabetes Complications ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 22/01/2007, Revision: 32, Status: Authorised

Case Medical Research ◽

10.31525/cmr-13b88da ◽

2019 ◽

Author(s):

Keyword(s):

Macular Degeneration ◽

Macular Edema ◽

Diabetes Complications ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Visudyne, verteporfin, Myopia, Degenerative,Macular Degeneration, Date of authorisation: 27/07/2000, Revision: 33, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1d8d135 ◽

2019 ◽

Author(s):

Keyword(s):

Macular Degeneration ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Macugen, pegaptanib, Wet Macular Degeneration, Date of authorisation: 31/01/2006, Revision: 15, Status: Withdrawn

Case Medical Research ◽

10.31525/cmr-16436b6 ◽

2019 ◽

Author(s):

Keyword(s):

Macular Degeneration ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Macular Edema,Uveitis, Date of authorisation: 26/07/2010, Revision: 10, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5ed96e ◽

2018 ◽

Author(s):

Keyword(s):

Macular Edema ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Beovu, brolucizumab, Wet Macular Degeneration, Date of authorisation: 13/02/2020, Status: Authorised

Case Medical Research ◽

10.31525/cmr-29b43aa ◽

2020 ◽

Author(s):

Keyword(s):

Macular Degeneration ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Macular Edema,Uveitis, Date of authorisation: 26/07/2010, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5ee338 ◽

2019 ◽

Author(s):

Keyword(s):

Macular Edema ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Fabrazyme, agalsidase beta, Fabry Disease, Date of authorisation: 03/08/2001, Revision: 26, Status: Authorised

Case Medical Research ◽

10.31525/cmr-19715f1 ◽

2019 ◽

Author(s):

Keyword(s):

Fabry Disease ◽

Agalsidase Beta ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Controloc Control, pantoprazole, Gastroesophageal Reflux, Date of authorisation: 11/06/2009, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-193042d ◽

2019 ◽

Author(s):

Keyword(s):

Gastroesophageal Reflux ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text